Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib

Abdulraheem Yacoub • 12 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Parsaclisib Ruxolitinib

Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, discusses a Phase II study exploring the use of parsaclisib, a PI3Kdelta inhibitor in myelofibrosis patients that show suboptimal responses to ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abdulraheem Yacoub

Current barriers to early intervention in myelofibrosis
1:58
Current barriers to early intervention in myelofibrosis
Abdulraheem Yacoub • 24 Aug 2024
The importance of early intervention in myelofibrosis
1:06
The importance of early intervention in myelofibrosis
Abdulraheem Yacoub • 24 Aug 2024
Final results of a Phase II study of add-on parsaclisib for pts with MF and suboptimal rux response
1:07
Final results of a Phase II study of add-on parsaclisib for pts with MF and suboptimal rux response
Abdulraheem Yacoub • 24 Aug 2024
The development of anti-fibrotic agents for treating myelofibrosis
2:00
The development of anti-fibrotic agents for treating myelofibrosis
Abdulraheem Yacoub • 24 Aug 2024

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Abdulraheem Yacoub • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Abdulraheem Yacoub • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Abdulraheem Yacoub • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Abdulraheem Yacoub • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals